Verve Therapeutics, Inc. (VERV) Tops Q3 EPS by 18c

Verve Therapeutics, Inc. (NASDAQ: VERV) reported Q3 EPS of ($0.72), $0.18 better than the analyst estimate of ($0.90). Revenue for the quarter came in at $3.12 million versus the consensus estimate of $963.67 thousand.

For earnings history and earnings-related data on Verve Therapeutics, Inc. (VERV) click here.

You May Also Be Interested In

• NVIDIA stock gains as SemiAnalysis sees H2 data center revenue 20% above consensus
• SanDisk stock target lifted at Bernstein to $3000 on new memory LTAs
• BMW slashes profit margin forecast to 1-3%; JPMorgan calls cut "radical" as stock hits six-year low